Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward

The Lancet

Volumn 372, Issue 9638, 2008, Pages 585-599

  Padian, Nancy S ^a   Buvé, Anne ^b   Balkus, Jennifer ^a   Serwadda, David ^c   Cates Jr , Ward ^d  

^a RTI INTERNATIONAL   (United States)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c MAKERERE UNIVERSITY   (Uganda)

^d FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; DAPIVIRINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; TENOFOVIR; VALACICLOVIR; VIVAGEL; ZIDOVUDINE;

ANTIVIRAL THERAPY; CIRCUMCISION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONDOM; DRUG EFFICACY; EPIDEMIC; HERPES; HERPES SIMPLEX VIRUS 2; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MEDICAL RESEARCH; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; SHORT COURSE THERAPY; SINGLE DRUG DOSE; UTERINE CERVIX CAP; VIRUS TRANSMISSION;

EID: 49349112505     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60885-5     Document Type: Review

References (187)

1. Jaffe H., Choi K., Thomas P., et al. National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men: part 1. Epidemiologic results. Ann Intern Med 99 (1983) 145-151
2. Cates Jr. W. Acquired immunodeficiency syndrome, sexually transmitted diseases, and epidemiology. Past lessons, present knowledge, and future opportunities. Am J Epidemiol 131 (1990) 749-758
3. Centers for Disease Control. Current trends prevention of acquired immune deficiency syndrome (AIDS): report of inter-agency recommendations. MMWR Morb Mortal Wkly Rep 32 (1983) 101-103
4. Callen M., and Berkowitz R. How to have sex in an epidemic: one approach (1983), News from the Front, New York
5. Davis K.R., and Weller S.C. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 31 (1999) 272-279
6. Hanenberg R., and Rojanapithayakorn W. Prevention as policy: how Thailand reduced STD and HIV transmission. AIDS Captions 3 (1996) 24-27
7. Nelson K.E., Celentano D.D., Eiumtrakol S., et al. Changes in sexual behavior and a decline in HIV Infection among young men in Thailand. N Engl J Med 335 (1996) 297-303
8. McKusick L., Wiley J.A., Coates T.J., et al. Reported changes in the sexual behavior of men at risk for AIDS, San Francisco, 1982-84-the AIDS behavioral research project. Public Health Rep 100 (1985) 622-629
9. Quinn T., Mann J., Curran J., and Piot P. AIDS in Africa: an epidemiologic paradigm. Science 234 (1986) 955-963
10. Becker M.H., and Joseph J.G. AIDS and behavioral change to reduce risk: a review. Am J Public Health 78 (1988) 394-410
11. Steinbrook R. One step forward, two steps back-will there ever be an AIDS vaccine?. N Engl J Med 357 (2007) 2653-2655
12. Francis D., and Petricciani J. The prospects for and pathways toward a vaccine for AIDS. N Engl J Med 313 (1985) 1586-1590
13. Day M. AIDS expert doubts vaccine will be found in near future. BMJ 334 (2007) 1133
14. Greenblatt R.M., Lukehart S.A., Plummer F.A., et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 2 (1988) 47-50
15. Bongaarts J., Reining P., Way P., and Conant F. The relationship between male circumcision and HIV infection in African populations. AIDS 3 (1989) 373-377
16. Grosskurth H., Mosha F., Todd J., et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 346 (1995) 530-536
17. Gregson S., Adamson S., Papaya S., et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med 4 (2007) e102
18. Kamali A., Quigley M., Nakiyingi J., et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 361 (2003) 645-652
19. Wawer M.J., Sewankambo N.K., Serwadda D., et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 353 (1999) 525-535
20. Auvert B., Taljaard D., Lagarde E., Sobngwi-Tambekou J., Sitta R., and Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med 2 (2005) e298
21. Bailey R.C., Moses S., Parker C.B., et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369 (2007) 643-656
22. Gray R.H., Kigozi G., Serwadda D., et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369 (2007) 657-666
23. UNAIDS. Male circumcision: Global trends and determinants of prevalence, safety and acceptability (2007), Joint United Nations Programme on HIV/AIDS, Geneva
24. Stein Z.A. HIV prevention: the need for methods women can use. Am J Public Health 80 (1990) 460-462
25. UNAIDS. AIDS epidemic update (2007), Joint United Nations Programme on HIV/AIDS, Geneva
26. Heise L.L., and Elias C. Transforming AIDS prevention to meet women's needs: A focus on developing countries. Soc Sci Med 40 (1995) 931-943
27. Abdool K. Barriers to preventing human immunodeficiency virus in women: experiences from KwaZulu-Natal, South Africa. J Am Med Womens Assoc 56 (2001) 193-196
28. d'Cruz-Grote D. Prevention of HIV infection in developing countries. Lancet 348 (1996) 1071-1074
29. Feldblum P., Adeiga A., Bakare R., et al. SAVVY vaginal gel (C31G) for prevention of HIV Infection: a randomized controlled trial in Nigeria. PLoS ONE 3 (2008) e1474
30. Van Damme L., Ramjee G., Alary M., et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360 (2002) 971-977
31. Van Damme L, Govinden R, Mirembe F, et-al. Phase III trial of 6% cellulose sulfate (CS) gel for the prevention of HIV transmission. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Sydney, Australia; July 22-25, 2007.
32. Population Council. Trial shows anti-HIV microbicide is safe, but does not prove it effective: research advances HIV prevention field. http://www.popcouncil.org/pdfs/Media%20Center/News_CarrResults_letter.pd f (accessed Feb 18, 2008).
33. Halpern V, Wang L, Obunge O, et al. Effectiveness of cellulose sulfate gel for prevention of HIV: results of the phase III trial in Nigeria. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Sydney, Australia; July 22-25, 2007.
34. Kreiss J., Ngugi E., Holmes K., et al. Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268 (1992) 477-482
35. Peterson L., Nanda K., Opoku B., et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE 2 (2007) e1312
36. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331 (1994) 1173-1180
37. Cardo D.M., Culver D.H., Ciesielski C.A., et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 337 (1997) 1485-1490
38. Microbicide Development Programme. Microbicides Development Programme (MDP) update: MDP301 phase III trial continues but one arm closes. http://www.mdp.mrc.ac.uk (accessed Feb 14, 2008).
39. NIAID. Workshop summary: scientific evidence on condom effectiveness for sexually transmitted disease (STD) prevention (2001), National Institute of Allergy and Infectious Diseases
40. Weller S., and Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 1 (2002) CD003255.
41. Carey R.F., Herman W.A., Retta S.M., Rinaldi J.E., Herman B.A., and Athey T.W. Effectiveness of latex condoms as a barrier to human immunodeficiency virus-sized particles under conditions of simulated use. Sex Transm Dis 19 (1992) 230-234
42. Holmes K.K., Levine R., and Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 82 (2004) 454-461
43. Van de Perre P., Jacobs D., and Sprecher-Goldberger S. The latex condom, an efficient barrier against sexual transmission of AIDS-related viruses. AIDS 1 (1987) 49-52
44. Conant M., Hardy D., Sernatinger J., Spicer D., and Levy J.A. Condoms prevent transmission of AIDS-associated retrovirus. JAMA 255 (1986) 1706
45. Lytle C.D., Routson L.B., Seaborn G.B., Dixon L.G., Bushar H.F., and Cyr W.H. An in vitro evaluation of condoms as barriers to a small virus. Sex Transm Dis 24 (1997) 161-164
46. Pinkerton S.D., and Abramson P.R. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 44 (1997) 1303-1312
47. Lagarde E., Auvert B., Chege J., et al. Condom use and its association with HIV/sexually transmitted diseases in four urban communities of sub-Saharan Africa. AIDS 15 (2001) S71-S78
48. Foss A.M., Hossain M., Vickerman P.T., and Watts C.H. A systematic review of published evidence on intervention impact on condom use in sub-Saharan Africa and Asia. Sex Transm Infect 83 (2007) 510-516
49. Lau J.T., Zhang J., Zhang L., et al. Comparing prevalence of condom use among 15 379 female sex workers injecting or not injecting drugs in China. Sex Transm Dis 34 (2007) 908-916
50. Cleland J., and Ali M.M. Sexual abstinence, contraception, and condom use by young African women: a secondary analysis of survey data. Lancet 368 (2006) 1788-1793
51. Ali M.M., and Cleland J. Sexual and reproductive behaviour among single women aged 15-24 in eight Latin American countries: a comparative analysis. Soc Sci Med 60 (2005) 1175-1185
52. Drew W.L., Blair M., Miner R.C., and Conant M. Evaluation of the virus permeability of a new condom for women. Sex Transm Dis 17 (1990) 110-112
53. Galvao L.W., Oliveira L.C., Diaz J., et al. Effectiveness of female and male condoms in preventing exposure to semen during vaginal intercourse: a randomized trial. Contraception 71 (2005) 130-136
54. French P.P., Latka M., Gollub E.L., Rogers C., Hoover D.R., and Stein Z.A. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis 30 (2003) 433-439
55. Feldblum P.J., Kuyoh M.A., Bwayo J.J., et al. Female condom introduction and sexually transmitted infection prevalence: results of a community intervention trial in Kenya. AIDS 15 (2001) 1037-1044
56. Fontanet A.L., Saba J., Chandelying V., et al. Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS 12 (1998) 1851-1859
57. Buck J., Kang M.S., van der Straten A., Khumalo-Sakutukwa G., Posner S., and Padian N. Barrier method preferences and perceptions among Zimbabwean women and their partners. AIDS Behav 9 (2005) 415-422
58. McNeil D. Redesigning a condom so women will use it. New York Times, Nov 13, 2007.
59. Thomsen S.C., Ombidi W., Toroitich-Ruto C., et al. A prospective study assessing the effects of introducing the female condom in a sex worker population in Mombasa, Kenya. Sex Transm Infect 82 (2006) 397-402
60. Female Health Company. What is FC2 female condom?. http://www.femalehealth.com/pdf/FC2%20factsheet%20layout2r.pdf (accessed Feb 18, 2008).
61. Coffey P.S., Kilbourne-Brook M., Austin G., Seamans Y., and Cohen J. Short-term acceptability of the PATH Woman's Condom among couples at three sites. Contraception 73 (2006) 588-593
62. Cervical Barriers Advancement Society. http://www.cervicalbarriers.org/information/otherFemCondom.cfm (accessed Dec 6, 2007).
63. Zhang Z., Schuler T., Zupancic M., et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286 (1999) 1353-1357
64. Howell A.L., Edkins R.D., Rier S.E., et al. Human immunodeficiency virus type 1 infection of cells and tissues from the upper and lower human female reproductive tract. J Virol 71 (1997) 3498-3506
65. Pudney J., Quayle A.J., and Anderson D.J. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 73 (2005) 1253-1263
66. Padian N.S., van der Straten A., Ramjee G., et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 370 (2007) 251-261
67. Barnhart K, Higgins J, MacKay H, Blithe D, Moench T. BufferGel with diaphragm found to be an effective contraceptive in two phase II/III trials. Microbicides Conference; Cape Town, South Africa; April 23-26, 2006.
68. Ramjee G., Shattock R., Delany S., McGowan I., Morar N., and Gottemoeller M. Microbicides 2006 conference. AIDS Res Ther 3 (2006) 25
69. Fleming D., and Wasserheit J. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 75 (1999) 3-17
70. Røttingen J.-A., Cameron D., and Garnett G. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV. How much really is known?. Sex Transm Dis 28 (2001) 579-597
71. McClelland R., Sangare L., Hassan W., et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 195 (2007) 698-702
72. Eron J., Gilliam B., Fiscus S., Dyer J., and Cohen M. HIV-1 shedding and chlamydial urethritis. JAMA 275 (1996) 36
73. Cohen M., Hoffman I., Royce R., et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 349 (1997) 1868-1873
74. Ghys P., Fransen K., Diallo O., et al. The association between cervicovaginal HIV shedding, sexually transmitted diseases, and immunosuppression in sex workers in Abidjan, Côte d'Ivoire. AIDS 11 (1997) F85-F93
75. Korenromp E., White R., Orroth K., et al. Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. J Infect Dis 191 suppl 1 (2005) S168-S178
76. Freeman E.E., Weiss H.A., Glynn J.R., Cross P.L., Whitworth J.A., and Hayes R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20 (2006) 73-83
77. Freeman E.E., Orroth K.K., White R.G., et al. Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect 83 suppl 1 (2007) i17-i24
78. White R., Orroth K., Glynn J., et al. Treating curable sexually transmitted infections to prevent HIV in Africa: still an effective control strategy?. J Acquir Immune Defic Syndr 47 (2008) 346-353
79. Watson-Jones D., Weiss H.A., Rusizoka M., et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 358 (2008) 1560-1571
80. Celum C., Wald A., Hughes J., et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008) 2109-2119
81. Celum C.L. The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 11 suppl 1 (2004) 36A-45A
82. Nagot N., Ouedraogo A., Foulongne V., et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 356 (2007) 790-799
83. Zuckerman R.A., Lucchetti A., Whittington W.L., et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 196 (2007) 1500-1508
84. Smith J.S., and Robinson N.J. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 186 suppl 1 (2002) S3-S28
85. Stanberry L.R. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11 suppl 3 (2004) 161A-169A
86. Stanberry L.R., Spruance S.L., Cunningham A.L., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347 (2002) 1652-1661
87. Szabo R., and Short R.V. How does male circumcision protect against HIV infection?. BMJ 320 (2000) 1592-1594
88. McCoombe S.G., and Short R.V. Potential HIV-1 target cells in the human penis. AIDS 20 (2006) 1491-1495
89. Patterson B.K., Landay A., Siegel J.N., et al. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 161 (2002) 867-873
90. Simon V., Ho D.D., and Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368 (2006) 489-504
91. O'Farrell N., Morison L., Moodley P., et al. Association between HIV and subpreputial penile wetness in uncircumcised men in South Africa. J Acquir Immune Defic Syndr 43 (2006) 69-77
92. Nasio J., Nagelkerke N., Mwatha A., Moses S., Ndinya-Achola J., and Plummer F. Genital ulcer disease among STD clinic attenders in Nairobi: association with HIV-1 and circumcision status. Int J STD AIDS 7 (1996) 410-414
93. Lavreys L., Rakwar J., Thompson M., et al. Effect of circumcision on incidence of human immunodeficiency virus type 1 and other sexually transmitted diseases: a prospective cohort study of trucking company employees in Kenya. J Infect Dis 180 (1999) 330-336
94. Gray R.H., Kiwanuka N., Quinn T.C., et al. Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team. AIDS 14 (2000) 2371-2381
95. Fergusson D.M., Boden J.M., and Horwood L.J. Circumcision status and risk of sexually transmitted infection in young adult males: an analysis of a longitudinal birth cohort. Pediatrics 118 (2006) 1971-1977
96. Baeten J.M., Richardson B.A., Lavreys L., et al. Female-to-male infectivity of HIV-1 among circumcised and uncircumcised Kenyan men. J Infect Dis 191 (2005) 546-553
97. Siegfried N., Muller M., Deeks J., et al. HIV and male circumcision-a systematic review with assessment of the quality of the studies. Lancet Infect Dis 5 (2005) 165-173
98. Weiss H.A., Quigley M.A., and Hayes R.J. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 14 (2000) 2361-2370
99. Weiss H.A., Halperin D., Bailey R.C., Hayes R.J., Schmid G., and Hankins C.A. Male circumcision for HIV prevention: from evidence to action?. AIDS 22 (2008) 567-574
100. Wawer M, Kigozi G, Serwadda D, et al. Trial of male circumcision in HIV+ men, Rakai, Uganda: effects in HIV+ men and in women partners. 15th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 3-6, 2008.
101. Kreiss J.K., and Hopkins S.G. The association between circumcision status and human immunodeficiency virus infection among homosexual men. J Infect Dis 168 (1993) 1404-1408
102. Buchbinder S.P., Vittinghoff E., Heagerty P.J., et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr 39 (2005) 82-89
103. Grulich A.E., Hendry O., Clark E., Kippax S., and Kaldor J.M. Circumcision and male-to-male sexual transmission of HIV. AIDS 15 (2001) 1188-1189
104. Koblin B., Husnik M.J., Colfax G., et al. Risk factors for HIV infection among men who have sex with men. AIDS 20 (2006) 731-739
105. Templeton DJ, Jin F, Prestage GP, et al. Circumcision status and risk of HIV seroconversion in the HIM cohort of homosexual men in Sydney. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Sydney, Australia; July 22-25, 2007.
106. UNAIDS and WHO. New data on male circumcision and HIV prevention: policy and programme implications; WHO/UNAIDS technical consultation male circumcision and HIV prevention: research implications for policy and programming montreux (2007), Joint United Nations Programme on HIV/AIDS and World Health Organization, Geneva
107. Kahn J.G., Marseille E., and Auvert B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med 3 (2006) e517
108. Williams B.G., Lloyd-Smith J.O., Gouws E., et al. The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med 3 (2006) e262
109. Westercamp N., and Bailey R.C. Acceptability of male circumcision for prevention of HIV/AIDS in sub-Saharan Africa: a review. AIDS Behav 11 (2007) 341-355
110. Gray R.H., Li X., Kigozi G., et al. The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS 21 (2007) 845-850
111. Ahmed A., Mbibi N.H., Dawam D., and Kalayi G.D. Complications of traditional male circumcision. Ann Trop Paediatr 19 (1999) 113-117
112. Mayatula V., and Mavundla T.R. A review on male circumcision procedures among South African blacks. Curationis 20 (1997) 16-20
113. Global Campaign for Microbicides. http://www.global-campaign.org/about_microbicides.htm (accessed Feb 5, 2008).
114. Roddy R.E., Zekeng L., Ryan K.A., Tamoufe U., Weir S.S., and Wong E.L. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 339 (1998) 504-510
115. Alliance for Microbicide Development. Microbicide candidates and ancillary devices in development: planned and funded clinical trials as of April 2008. http://www.microbicide.org (accessed April 4, 2008).
116. Malcolm R.K., Woolfson A.D., Toner C.F., Morrow R.J., and McCullagh S.D. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 56 (2005) 954-956
117. Alliance for Microbicide Development. Microbicide candidates in ongoing clinical trials: summary as of April 2008. http://www.microbicide.org (accessed April 4, 2008).
118. Hardy E., Hebling E.M., Sousa M.H., Almeida A.F., and Amaral E. Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences. Contraception 76 (2007) 126-131
119. Guay L.A., Musoke P., Fleming T., et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354 (1999) 795-802
120. John G., Nduati R., Mbori-Ngacha D., et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 183 (2001) 206-212
121. Garcia P.M., Kalish L.A., Pitt J., et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 341 (1999) 394-402
122. Musoke P., Guay L.A., Bagenda D., et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 13 (1999) 479-486
123. Mirochnick M., Fenton T., Gagnier P., et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 178 (1998) 368-374
124. Moodley D., Moodley J., Coovadia H., et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 187 (2003) 725-735
125. Dorenbaum A., Cunningham C.K., Gelber R.D., et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 288 (2002) 189-198
126. Chaisilwattana P., Chokephaibulkit K., Chalermchockcharoenkit A., et al. Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. Clin Infect Dis 35 (2002) 1405-1413
127. Dabis F., Bequet L., Ekouevi D.K., et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 19 (2005) 309-318
128. Mandelbrot L., Landreau-Mascaro A., Rekacewicz C., et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 285 (2001) 2083-2093
129. Shaffer N., Chuachoowong R., Mock P.A., et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 353 (1999) 773-780
130. The PETRA Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 359 (2002) 1178-1186
131. Kumwenda N.I., Hoover D.R., Mofenson L., et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med (2008) 10.1056/NEJMoa0801941 published online June 4.
132. Six Week Extended-dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to six weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet (in press).
133. Thomas T, Masaba R, Ndivo R, et al. Prevention of mother-to-child Transmission of HIV-1 among breastfeeding mothers using HAART: the Kisumu breastfeeding study, Kisumu, Kenya, 2003-2007. 15th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 3-6, 2008.
134. WHO. Prevention of HIV in infants and young children: review of evidence and WHO's activities (2002), World Health Organization, Geneva
135. WHO. Medical eligibility criteria for contraceptive use. 3rd edition (2004), World Health Organization, Geneva
136. Sweat M.D., O'Reilly K.R., Schmid G.P., Denison J., and de Zoysa I. Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. AIDS 18 (2004) 1661-1671
137. Stover J., Fuchs N., Halperin D., Gibbons A., and Gillespie D. Issue brief: adding family planning to PMTCT sites increases the benefits of PMTCT. http://www.usaid.gov/our_work/global_health/pop/news/issue_briefs/pmtct_ issue_brief.pdf (accessed April 4, 2008).
138. Reynolds H.W., Janowitz B., Homan R., and Johnson L. The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis 33 (2006) 350-356
139. Duerr A., Hurst S., Kourtis A.P., Rutenberg N., and Jamieson D.J. Integrating family planning and prevention of mother-to-child HIV transmission in resource-limited settings. Lancet 366 (2005) 261-263
140. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access; recommendations for a public health approach (2006), World Health Organization, Geneva
141. Liu A.Y., Grant R.M., and Buchbinder S.P. Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 296 (2006) 863-865
142. Subbarao S., Otten R.A., Ramos A., et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 194 (2006) 904-911
143. Garcia-Lerma J.G., Otten R.A., Qari S.H., et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5 (2008) e28
144. Population Council, PROJECT: nonclinical laboratory studies: PC-815 (Carraguard + MIV-150). http://www.popcouncil.org/projects/MIC_PC-815NonclinLab.html (accessed Feb 20, 2008).
145. Quinn T.C., Wawer M.J., Sewankambo N., et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342 (2000) 921-929
146. Fiore J.R., Zhang Y.J., Bjorndal A., et al. Biological correlates of HIV-1 heterosexual transmission. AIDS 11 (1997) 1089-1094
147. Pedraza M.A., del Romero J., Roldan F., et al. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr 21 (1999) 120-125
148. Tovanabutra S., Robison V., Wongtrakul J., et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 29 (2002) 275-283
149. Fideli U.S., Allen S.A., Musonda R., et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 17 (2001) 901-910
150. Fiore J.R., Suligoi B., Saracino A., et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 17 (2003) 2169-2176
151. Cu-Uvin S., Caliendo A.M., Reinert S., et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 14 (2000) 415-421
152. Vernazza P.L., Troiani L., Flepp M.J., et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 14 (2000) 117-121
153. Neto L.P., Vieira N.F.R., Soprani M., et al. Longitudinal comparison between plasma and seminal HIV-1 viral loads during antiretroviral treatment. Rev Soc Bras Med Trop 36 (2003) 689-694
154. Castilla J., Del Romero J., Hernando V., Marincovich B., Garcia S., and Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 40 (2005) 96-101
155. Barreiro P., del Romero J., Leal M., et al. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 43 (2006) 324-326
156. Melo M, Varella I, Nielsen K, Turella L, Santos B. Demographic characteristics, sexual transmission and CD4 progression among heterosexual HIV-1 serodiscordant couples followed in Porto Alegre, Brazil. XVI International AIDS Conference; Toronto, ON, Canada; Aug 13-18, 2006.
157. UNAIDS. Antiretroviral therapy and sexual transmission of HIV. http://data.unaids.org/pub/PressStatement/2008/080201_hivtransmission_en .pdf (accessed Feb 6, 2008).
158. HIV Prevention Trials Network. HPTN 052. http://www.hptn.org/research_studies/hptn052.asp (accessed April 15, 2008).
159. HIV Vaccines and Microbicides Resource Tracking Working Group. Building a comprehensive response. Funding for HIV vaccines, microbicides and other new prevention options: 2000-2006. http://www.hivresourcetracking.org (accessed March 1, 2008).
160. Johnston M.I., and Fauci A.S. An HIV vaccine-evolving concepts. N Engl J Med 356 (2007) 2073-2081
161. Flynn N., Forthal D., Harro C., et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191 (2005) 654-665
162. Pitisuttithum P., Gilbert P., Gurwith M., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194 (2006) 1661-1671
163. Craib K.J., Strathdee S.A., Hogg R.S., et al. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection. J Infect Dis 176 (1997) 798-800
164. Lefrere J.J., Roudot-Thoraval F., Mariotti M., et al. The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection. J Infect Dis 177 (1998) 1541-1548
165. Merck. Vaccination and enrollment are discontinued in phase II trials of merck's investigational HIV vaccine candidate: interim analysis of STEP study shows vaccine was not effective. http://www.hvtn.org/pdf/FINAL_HIV_Vaccine_Press_Release.pdf (accessed Jan 15, 2008).
166. Kresge K.J. Additional data released from the STEP trial raises questions about whether the vaccine may have increased the risk of HIV infection. IAVI Report. http://www.iavireport.org/Issues/Issue11-5/Step.asp (accessed Jan 15, 2008).
167. Jefferys R. Scanning the scientific horizon. IAVI Report. http://www.iavireport.org/Issues/Issue12-1/Scanning.asp (accessed March 4, 2008).
168. Walker B., and Burton D. Towards and AIDS vaccine. Science 320 (2008) 760-764
169. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 6 (2006) 930-939
170. Montefiori D., Sattentau Q., Flores J., Esparza J., and Mascola J. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 4 (2007) e348
171. Kulkarni P.S., Butera S.T., and Duerr A.C. Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 5 (2003) 87-103
172. Deeks S.G., and Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27 (2007) 406-416
173. UNAIDS. 2006 Report on the global AIDS epidemic. 2006.
174. Bertozzi S.M., Laga M., Bautista-Arredondo S., and Coutinho A. Making HIV prevention programmes work. Lancet (2008) 10.1016/S0140-6736(08)60889-2 published online Aug 6.
175. Institute of Medicine (IOM). Methodological Challenges in Biomedical HIV Prevention Trials (2008), The National Academies Press, Washington, DC
176. Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol (in press).
177. Jespers V., Laga M., Van Herrewege Y., and Vanham G. Microbicides a long and bumpy road to success?. AIDS Rev 9 (2007) 61-62
178. Desrosiers R. Scientific obstacles to an effective HIV Vaccine. Plenary at the 15th Conference of Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 3-6, 2008.
179. Cohen J. Retrovirus meeting: Back-to-basics push as HIV prevention struggles. Science 319 (2008) 888
180. van de Wijgert J.H., and Shattock R.J. Vaginal microbicides: moving ahead after an unexpected setback. AIDS 21 (2007) 2369-2376
181. Cohen M.S., Hellmann N., Levy J.A., DeCock K., and Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 118 (2008) 1244-1254
182. PEPFAR. Prevention for Positives. http://www.pepfar.gov/press/92934.htm (accessed April 24, 2008).
183. Cates Jr. W., and Hinman A.R. AIDS and absolutism-the demand for perfection in prevention. N Engl J Med 327 (1992) 492-494
184. Cassell M.M., Halperin D.T., Shelton J.D., and Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention?. BMJ 332 (2006) 605-607
185. Cohen J. HIV/AIDS: Prevention cocktails: combining tools to stop HIV's spread. Science 309 (2005) 1002-1005
186. Coates T.J., Richter L., and Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet (2008) 10.1016/S0140-6736(08)60886-7 published online Aug 6.
187. United Nations General Assembly. Declaration of Commitment on HIV/AIDS and Political Declaration on HIV/AIDS: midway to the Millennium Development Goals. Report of the Secretary-General. New York: United Nations, 2008.